# CJC-1295 Buy

> A constructed reference on the CJC-1295 supply landscape — what the literature, the FDA, and WADA actually say about acquiring a halted Phase 2 peptide.

## Pages

- [CJC-1295 Buy — Independent dossier on a halted GHRH analog and its supply landscape](/index.md): What the published research, FDA Pharmacy Compounding Advisory Committee briefings, and WADA standards say about CJC-1295 — a long-acting GHRH analog whose Phase 2 program was terminated in 2006 and which the FDA placed in 503A Category 2 in 2023.
- [CJC-1295 reported effects, community signals, and safety cautions](/effects.md): What the research-use community reports about CJC-1295 — benefits, adverse effects, and the cited safety cautions that matter — in plain language, with the evidence clearly labeled.
- [CJC-1295 Research — Mechanism, Phase 1 PK/PD, pulsatility, halted Phase 2, and forensic analytics](/research.md): A peer-reviewed summary of CJC-1295 research: GHRH-receptor mechanism, DAC bioconjugate pharmacokinetics, the Teichman 2006 Phase 1 data, the Ionescu pulsatility paper, the halted NCT00267527 trial, and recent WADA analytical methodology.
- [CJC-1295 Dosage Research — What animal and Phase 1 human studies reported](/dosage.md): A research-context summary of the doses, routes, and intervals studied in published CJC-1295 work — Jetté 2005 rat PK, Alba 2006 GHRH-knockout mouse, Teichman 2006 Phase 1 human PK/PD. Not prescriptive guidance.
- [CJC-1295 Buy — Frequently asked questions on legality, supply, vendors, and the WADA listing](/faq.md): Editorial answers to the questions that recur in search around buying CJC-1295: U.S. legal status, why compounding pharmacy supply is restricted, DAC vs non-DAC, vendor verification, anti-doping consequences, and what the published research actually shows.
- [CJC-1295 References — Peer-reviewed papers, regulatory filings, and analytical standards](/references.md): Full citation list for the CJC-1295 dossier: peer-reviewed PK/PD and mechanism papers from 2005-2024, the ClinicalTrials.gov record for NCT00267527, FDA Pharmacy Compounding Advisory Committee briefings from 2024, and the 2025 WADA Prohibited List.
- [About CJC-1295 Buy — Independent editorial publisher, not a vendor or a clinic](/about.md): CJC-1295 Buy is an independent editorial dossier on the published research, regulatory, and analytical record of CJC-1295. The site is not a clinic, does not employ clinicians, does not provide medical advice, and does not sell or distribute any product.
- [Contact CJC-1295 Buy — Editorial corrections and source suggestions](/contact.md): Editorial contact for CJC-1295 Buy. Use this form for factual corrections, new source suggestions, and editorial questions. We do not respond to vendor outreach, purchasing inquiries, or requests for medical advice.